CVE-2020-10627
An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data.
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (0.48%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.
- CVSS 3.1
- 8.1 HIGHCVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
- EPSS
- 0.48% probability · 40th percentile
- CISA KEV
- Not listed
- Weakness
- CWE-284
- Affected
- insulet/omnipod insulin management system firmware
- Source
- ics-cert@hq.dhs.gov
References
- https://us-cert.cisa.gov/ics/advisories/icsma-20-079-01Third Party Advisory, US Government Resource
- https://www.myomnipod.com/security-bulletinsVendor Advisory
- https://us-cert.cisa.gov/ics/advisories/icsma-20-079-01Third Party Advisory, US Government Resource
- https://www.myomnipod.com/security-bulletinsVendor Advisory
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.